
## Nicolas Wentzensen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7779787/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Using Natural Language Processing to Improve Discrete Data Capture From Interpretive Cervical Biopsy Diagnoses at a Large Health Care Organization. Archives of Pathology and Laboratory Medicine, 2023, 147, 222-226.	1.2	1
2	Cohort Profile: The Ovarian Cancer Cohort Consortium (OC3). International Journal of Epidemiology, 2022, 51, e73-e86.	0.9	5
3	High Prediagnosis Inflammation-Related Risk Score Associated with Decreased Ovarian Cancer Survival. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 443-452.	1.1	2
4	Reproductive factors do not influence survival with ovarian cancer. Cancer Epidemiology Biomarkers and Prevention, 2022, , cebp.1091.2021.	1.1	1
5	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. European Journal of Human Genetics, 2022, 30, 349-362.	1.4	23
6	Inflammatory markers in women with reported benign gynecologic pathology: an analysis of the prostate, lung, colorectal and ovarian cancer screening trial Annals of Epidemiology, 2022, 68, 1-8.	0.9	1
7	Cervical Precancers and Cancers Attributed to HPV Types by Race and Ethnicity: Implications for Vaccination, Screening, and Management. Journal of the National Cancer Institute, 2022, 114, 845-853.	3.0	12
8	What Contributes to Pregnancy Complications Among Women With Cervical Intraepithelial Neoplasia Grade 3?. Annals of Internal Medicine, 2022, 175, 293-294.	2.0	0
9	Automated Evaluation of p16/Ki-67 Dual-Stain Cytology as a Biomarker for Detection of Anal Precancer in Men Who Have Sex With Men and Are Living With Human Immunodeficiency Virus. Clinical Infectious Diseases, 2022, 75, 1565-1572.	2.9	6
10	Metaâ€analysis of agreement/concordance statistics in studies comparing self―vs clinicianâ€collected samples for <scp>HPV</scp> testing in cervical cancer screening. International Journal of Cancer, 2022, 151, 308-312.	2.3	31
11	Reply to: Comments on "Metaâ€analysis of agreement/concordance statistics in studies comparing self― vs clinicianâ€collected samples for HPV testing in cervical cancer screening― International Journal of Cancer, 2022, 151, 484-487.	2.3	0
12	Computable Guidelines and Clinical Decision Support for Cervical Cancer Screening and Management to Improve Outcomes and Health Equity. Journal of Women's Health, 2022, 31, 462-468.	1.5	14
13	Racial and Ethnic Differences in Hysterectomy-Corrected Uterine Corpus Cancer Mortality by Stage and Histologic Subtype. JAMA Oncology, 2022, 8, 895.	3.4	57
14	Different human papillomavirus types share early natural history transitions in immunocompetent women. International Journal of Cancer, 2022, 151, 920-929.	2.3	5
15	Redesign of a rapid, lowâ€cost <scp>HPV</scp> typing assay to support riskâ€based cervical screening and management. International Journal of Cancer, 2022, 151, 1142-1149.	2.3	12
16	Accuracy and Efficiency of Deep-Learning–Based Automation of Dual Stain Cytology in Cervical Cancer Screening. Journal of the National Cancer Institute, 2021, 113, 72-79.	3.0	82
17	The Orderly Incorporation of Continuing Technologic Advances Into Cervical Cancer Screening. Journal of the National Cancer Institute, 2021, 113, 231-233.	3.0	3
18	Expanding Our Understanding of Ovarian Cancer Risk: The Role of Incomplete Pregnancies. Journal of the National Cancer Institute, 2021, 113, 301-308.	3.0	8

#	Article	IF	CITATIONS
19	Trends in hysterectomyâ€corrected uterine cancer mortality rates during 2002 to 2015: mortality of nonendometrioid cancer on the rise?. International Journal of Cancer, 2021, 148, 584-592.	2.3	5
20	Mendelian randomization analyses suggest a role for cholesterol in the development of endometrial cancer. International Journal of Cancer, 2021, 148, 307-319.	2.3	35
21	Risk of cervical precancer and cancer among uninsured and underserved women from 2009 to 2017. American Journal of Obstetrics and Gynecology, 2021, 224, 366.e1-366.e32.	0.7	14
22	Infiltrating T-cell markers in cervical carcinogenesis: a systematic review and meta-analysis. British Journal of Cancer, 2021, 124, 831-841.	2.9	39
23	Pregnancy outcomes and risk of endometrial cancer: A pooled analysis of individual participant data in the Epidemiology of Endometrial Cancer Consortium. International Journal of Cancer, 2021, 148, 2068-2078.	2.3	14
24	Summary of Current Guidelines for Cervical Cancer Screening and Management of Abnormal Test Results: 2016–2020. Journal of Women's Health, 2021, 30, 5-13.	1.5	31
25	Cervical Screening Performance. American Journal of Clinical Pathology, 2021, 155, 616-620.	0.4	3
26	Genital powder use and risk of uterine cancer: A pooled analysis of prospective studies. International Journal of Cancer, 2021, 148, 2692-2701.	2.3	4
27	Smoking Modifies Pancreatic Cancer Risk Loci on 2q21.3. Cancer Research, 2021, 81, 3134-3143.	0.4	8
28	Treatment approaches for women with positive cervical screening results in low-and middle-income countries. Preventive Medicine, 2021, 144, 106439.	1.6	10
29	Cervical Cancer Screening—Past, Present, and Future. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 432-434.	1.1	8
30	Hidden moverâ€ <b>s</b> tayer model for disease progression accounting for misclassified and partially observed diagnostic tests: Application to the natural history of human papillomavirus and cervical precancer. Statistics in Medicine, 2021, 40, 3460-3476.	0.8	1
31	The relationship of human papillomavirus and cytology co-testing results with endometrial and ovarian cancer diagnoses. Gynecologic Oncology, 2021, 161, 297-303.	0.6	3
32	Associations between Genetically Predicted Circulating Protein Concentrations and Endometrial Cancer Risk. Cancers, 2021, 13, 2088.	1.7	10
33	Joint IARC/NCI International Cancer Seminar Series Report: expert consensus on future directions for ovarian carcinoma research. Carcinogenesis, 2021, 42, 785-793.	1.3	6
34	Genetic and Epigenetic Variations of HPV52 in Cervical Precancer. International Journal of Molecular Sciences, 2021, 22, 6463.	1.8	9
35	Quantifying procedural pain associated with office gynecologic tract sampling methods. Gynecologic Oncology, 2021, 162, 128-133.	0.6	6
36	Hepcidin-regulating iron metabolism genes and pancreatic ductal adenocarcinoma: a pathway analysis of genome-wide association studies. American Journal of Clinical Nutrition, 2021, 114, 1408-1417.	2.2	9

#	Article	IF	CITATIONS
37	Liquid Biopsy for Cancer Detection: Clinical and Epidemiologic Considerations. Clinical Cancer Research, 2021, 27, 5733-5735.	3.2	4
38	Talc, body powder, and ovarian cancer: A summary of the epidemiologic evidence. Gynecologic Oncology, 2021, 163, 199-208.	0.6	12
39	2020 list of human papillomavirus assays suitable for primary cervical cancer screening. Clinical Microbiology and Infection, 2021, 27, 1083-1095.	2.8	116
40	Tao brush endometrial cytology is a sensitive diagnostic tool for cancer and hyperplasia among women presenting to clinic with abnormal uterine bleeding. Cancer Medicine, 2021, 10, 7040-7047.	1.3	8
41	Epidemiology of anal human papillomavirus infection and high-grade squamous intraepithelial lesions in 29 900 men according to HIV status, sexuality, and age: a collaborative pooled analysis of 64 studies. Lancet HIV,the, 2021, 8, e531-e543.	2.1	77
42	Phylogenomic Analysis of Human Papillomavirus Type 31 and Cervical Carcinogenesis: A Study of 2093 Viral Genomes. Viruses, 2021, 13, 1948.	1.5	7
43	Impact of COVID-19 on cervical cancer screening: Challenges and opportunities to improving resilience and reduce disparities. Preventive Medicine, 2021, 151, 106596.	1.6	68
44	STRIDES - STudying Risk to Improve DisparitiES in Cervical Cancer in Mississippi – Design and baseline results of a Statewide Cohort Study. Preventive Medicine, 2021, 153, 106740.	1.6	9
45	Rethinking Cervical Cancer Screening in Brazil Post COVID-19: A Global Opportunity to Adopt Higher Impact Strategies. Cancer Prevention Research, 2021, 14, 919-926.	0.7	5
46	Multisite Clinical Validation of Isothermal Amplification-Based SARS-CoV-2 Detection Assays Using Different Sampling Strategies. Microbiology Spectrum, 2021, 9, e0084621.	1.2	4
47	Development of a Large Biorepository of Cervical Specimens for theImproving Risk Informed HPV Screening Study (IRIS). Journal of Clinical Virology, 2021, 145, 105014.	1.6	2
48	Ageâ€specific prevalence of human papillomavirus and abnormal cytology at baseline in a diverse statewide prospective cohort of individuals undergoing cervical cancer screening in Mississippi. Cancer Medicine, 2021, 10, 8641-8650.	1.3	9
49	The IARC Perspective on Cervical Cancer Screening. New England Journal of Medicine, 2021, 385, 1908-1918.	13.9	125
50	The Improving Risk Informed HPV Screening (IRIS) Study: Design and Baseline Characteristics. Cancer Epidemiology Biomarkers and Prevention, 2021, , cebp.0865.2021.	1.1	3
51	Absolute risks of cervical precancer among women who fulfill exiting guidelines based on HPV and cytology cotesting. International Journal of Cancer, 2020, 146, 617-626.	2.3	5
52	Response to Pretorius and Belinson. Journal of the National Cancer Institute, 2020, 112, 115-116.	3.0	0
53	A Transcriptome-Wide Association Study Identifies Novel Candidate Susceptibility Genes for Pancreatic Cancer. Journal of the National Cancer Institute, 2020, 112, 1003-1012.	3.0	59
54	Association of Powder Use in the Genital Area With Risk of Ovarian Cancer. JAMA - Journal of the American Medical Association, 2020, 323, 49.	3.8	41

#	Article	IF	CITATIONS
55	Analysis of DNA methylation in endometrial biopsies to predict risk of endometrial cancer. Gynecologic Oncology, 2020, 156, 682-688.	0.6	20
56	Relationships of p16 Immunohistochemistry and Other Biomarkers With Diagnoses of Cervical Abnormalities: Implications for LAST Terminology. Archives of Pathology and Laboratory Medicine, 2020, 144, 725-734.	1.2	30
57	A prospective clinical cohort study of women at increased risk for endometrial cancer. Gynecologic Oncology, 2020, 156, 169-177.	0.6	17
58	Design and feasibility of a novel program of cervical screening in Nigeria: self-sampled HPV testing paired with visual triage. Infectious Agents and Cancer, 2020, 15, 60.	1.2	27
59	A study of type-specific HPV natural history and implications for contemporary cervical cancer screening programs. EClinicalMedicine, 2020, 22, 100293.	3.2	109
60	Systematic review and meta-analysis of studies assessing the relationship between statin use and risk of ovarian cancer. Cancer Causes and Control, 2020, 31, 869-879.	0.8	18
61	Ovarian Cancer Risk Factor Associations by Primary Anatomic Site: The Ovarian Cancer Cohort Consortium. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2010-2018.	1.1	6
62	Mendelian Randomization Analysis of n-6 Polyunsaturated Fatty Acid Levels and Pancreatic Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2735-2739.	1.1	6
63	Statistical approaches using longitudinal biomarkers for disease early detection: A comparison of methodologies. Statistics in Medicine, 2020, 39, 4405-4420.	0.8	4
64	A demonstration of automated visual evaluation of cervical images taken with a smartphone camera. International Journal of Cancer, 2020, 147, 2416-2423.	2.3	46
65	Challenges Associated With Cervical Cancer Screening and Management in Obese Women. Journal of Lower Genital Tract Disease, 2020, 24, 184-191.	0.9	9
66	Genital Powder Use and Ovarian Cancer—Reply. JAMA - Journal of the American Medical Association, 2020, 323, 2096.	3.8	0
67	Genome-Wide Gene–Diabetes and Gene–Obesity Interaction Scan in 8,255 Cases and 11,900 Controls from PanScan and PanC4 Consortia. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 1784-1791.	1.1	5
68	Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). Clinical Cancer Research, 2020, 26, 5411-5423.	3.2	43
69	Association of <scp>HPV35</scp> with cervical carcinogenesis among women of African ancestry: Evidence of viralâ€host interaction with implications for disease intervention. International Journal of Cancer, 2020, 147, 2677-2686.	2.3	44
70	A study of the risks of CIN3+ detection after multiple rounds of HPV testing: Results of the 15â€year cervical cancer screening experience at Kaiser Permanente Northern California. International Journal of Cancer, 2020, 147, 1612-1620.	2.3	15
71	Racial differences in HPV type 16 prevalence in women with ASCUS of the uterine cervix. Cancer Cytopathology, 2020, 128, 528-534.	1.4	12
72	2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors. Journal of Lower Genital Tract Disease, 2020, 24, 102-131.	0.9	608

#	Article	IF	CITATIONS
73	Risk Estimates Supporting the 2019 ASCCP Risk-Based Management Consensus Guidelines. Journal of Lower Genital Tract Disease, 2020, 24, 132-143.	0.9	116
74	Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival. Gynecologic Oncology, 2020, 158, 702-709.	0.6	15
75	Genome-Wide Association Study Data Reveal Genetic Susceptibility to Chronic Inflammatory Intestinal Diseases and Pancreatic Ductal Adenocarcinoma Risk. Cancer Research, 2020, 80, 4004-4013.	0.4	5
76	The Risk of Ovarian Cancer Increases with an Increase in the Lifetime Number of Ovulatory Cycles: An Analysis from the Ovarian Cancer Cohort Consortium (OC3). Cancer Research, 2020, 80, 1210-1218.	0.4	35
77	Endogenous estradiol and inflammation biomarkers: potential interacting mechanisms of obesity-related disease. Cancer Causes and Control, 2020, 31, 309-320.	0.8	16
78	Mutations in the HPV16 genome induced by APOBEC3 are associated with viral clearance. Nature Communications, 2020, 11, 886.	5.8	52
79	Association of Anti-Mullerian Hormone, Follicle-Stimulating Hormone, and Inhibin B with Risk of Ovarian Cancer in the Janus Serum Bank. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 636-642.	1.1	9
80	Identification of HPV genotypes causing cervical precancer using tissueâ€based genotyping. International Journal of Cancer, 2020, 146, 2836-2844.	2.3	13
81	Reproductive and Hormonal Factors and Risk of Ovarian Cancer by Tumor Dominance: Results from the Ovarian Cancer Cohort Consortium (OC3). Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 200-207.	1.1	11
82	Risk assessment of endometrial cancer and endometrial intraepithelial neoplasia in women with abnormal bleeding and implications for clinical management algorithms. American Journal of Obstetrics and Gynecology, 2020, 223, 549.e1-549.e13.	0.7	40
83	2019 ASCCP Risk-Based Management Consensus Guidelines. Journal of Lower Genital Tract Disease, 2020, 24, 90-101.	0.9	66
84	A Study of Partial Human Papillomavirus Genotyping in Support of the 2019 ASCCP Risk-Based Management Consensus Guidelines. Journal of Lower Genital Tract Disease, 2020, 24, 144-147.	0.9	48
85	An Introduction to the 2019 ASCCP Risk-Based Management Consensus Guidelines. Journal of Lower Genital Tract Disease, 2020, 24, 87-89.	0.9	26
86	Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk. Cancer Research, 2019, 79, 505-517.	0.4	49
87	Analgesic Use and Ovarian Cancer Risk: An Analysis in the Ovarian Cancer Cohort Consortium. Journal of the National Cancer Institute, 2019, 111, 137-145.	3.0	43
88	Antibodies Against <i>Chlamydia trachomatis</i> and Ovarian Cancer Risk in Two Independent Populations. Journal of the National Cancer Institute, 2019, 111, 129-136.	3.0	56
89	Postmenopausal Androgen Metabolism and Endometrial Cancer Risk in the Women's Health Initiative Observational Study. JNCI Cancer Spectrum, 2019, 3, pkz029.	1.4	30
90	Evaluation of TypeSeq, a Novel High-Throughput, Low-Cost, Next-Generation Sequencing-Based Assay for Detection of 51 Human Papillomavirus Genotypes. Journal of Infectious Diseases, 2019, 220, 1609-1619.	1.9	17

#	Article	IF	CITATIONS
91	High Levels of C-Reactive Protein Are Associated with an Increased Risk of Ovarian Cancer: Results from the Ovarian Cancer Cohort Consortium. Cancer Research, 2019, 79, 5442-5451.	0.4	36
92	Circulating estrogens and postmenopausal ovarian and endometrial cancer risk among current hormone users in the Women's Health Initiative Observational Study. Cancer Causes and Control, 2019, 30, 1201-1211.	0.8	13
93	Circulating androgens and postmenopausal ovarian cancer risk in the Women's Health Initiative Observational Study. International Journal of Cancer, 2019, 145, 2051-2060.	2.3	15
94	Association between genetically predicted polycystic ovary syndrome and ovarian cancer: a Mendelian randomization study. International Journal of Epidemiology, 2019, 48, 822-830.	0.9	22
95	Molecular Classification of Epithelial Ovarian Cancer Based on Methylation Profiling: Evidence for Survival Heterogeneity. Clinical Cancer Research, 2019, 25, 5937-5946.	3.2	50
96	Hysterectomy-Corrected Uterine Corpus Cancer Incidence Trends and Differences in Relative Survival Reveal Racial Disparities and Rising Rates of Nonendometrioid Cancers. Journal of Clinical Oncology, 2019, 37, 1895-1908.	0.8	169
97	Clinical Evaluation of Human Papillomavirus Screening With p16/Ki-67 Dual Stain Triage in a Large Organized Cervical Cancer Screening Program. JAMA Internal Medicine, 2019, 179, 881.	2.6	98
98	Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women. Cancer Medicine, 2019, 8, 2503-2513.	1.3	6
99	Development of the TypeSeq Assay for Detection of 51 Human Papillomavirus Genotypes by Next-Generation Sequencing. Journal of Clinical Microbiology, 2019, 57, .	1.8	27
100	Metaâ€analysis of the accuracy of p16 or p16/Kiâ€67 immunocytochemistry versus HPV testing for the detection of CIN2+/CIN3+ in triage of women with minor abnormal cytology. Cancer Cytopathology, 2019, 127, 169-180.	1.4	31
101	Circulating inflammation markers and colorectal adenoma risk. Carcinogenesis, 2019, 40, 765-770.	1.3	14
102	Human papillomavirus 16 sub-lineage dispersal and cervical cancer risk worldwide: Whole viral genome sequences from 7116 HPV16-positive women. Papillomavirus Research (Amsterdam,) Tj ETQq0 0 0 rgB	T/Ønv∎rloc	k 1 <b>0</b> 87f 50 29
103	Development and validation of circulating CA125 prediction models in postmenopausal women. Journal of Ovarian Research, 2019, 12, 116.	1.3	12
104	Role of Screening History in Clinical Meaning and Optimal Management of Positive Cervical Screening Results. Journal of the National Cancer Institute, 2019, 111, 820-827.	3.0	20
105	Agnostic Pathway/Gene Set Analysis of Genome-Wide Association Data Identifies Associations for Pancreatic Cancer. Journal of the National Cancer Institute, 2019, 111, 557-567.	3.0	21
106	5-Year Prospective Evaluation of Cytology, Human Papillomavirus Testing, and Biomarkers for Detection of Anal Precancer in Human Immunodeficiency Virus–Positive Men Who Have Sex With Men. Clinical Infectious Diseases, 2019, 69, 631-638.	2.9	29
107	An Observational Study of Deep Learning and Automated Evaluation of Cervical Images for Cancer Screening. Journal of the National Cancer Institute, 2019, 111, 923-932.	3.0	249
108	Five-Year Risk of Cervical Precancer Following p16/Ki-67 Dual-Stain Triage of HPV-Positive Women. JAMA Oncology, 2019, 5, 181.	3.4	79

#	Article	IF	CITATIONS
109	Prediagnostic Serum Levels of Fatty Acid Metabolites and Risk of Ovarian Cancer in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 189-197.	1.1	33
110	Childhood Overweight, Tallness, and Growth Increase Risks of Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 183-188.	1.1	14
111	Large-scale in-silico identification of a tumor-specific antigen pool for targeted immunotherapy in triple-negative breast cancer. Oncotarget, 2019, 10, 2515-2529.	0.8	11
112	Validation of a Human Papillomavirus (HPV) DNA Cervical Screening Test That Provides Expanded HPV Typing. Journal of Clinical Microbiology, 2018, 56, .	1.8	18
113	Automated Cervical Screening and Triage, Based on HPV Testing and Computer-Interpreted Cytology. Journal of the National Cancer Institute, 2018, 110, 1222-1228.	3.0	12
114	Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study. British Journal of Cancer, 2018, 118, 1123-1129.	2.9	15
115	Relative Performance of HPV and Cytology Components of Cotesting in Cervical Screening. Journal of the National Cancer Institute, 2018, 110, 501-508.	3.0	116
116	Eurogin roadmap 2017: Triage strategies for the management of <scp>HPV</scp> â€positive women in cervical screening programs. International Journal of Cancer, 2018, 143, 735-745.	2.3	124
117	Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. Nature Communications, 2018, 9, 556.	5.8	188
118	Birth weight and the risk of histological subtypes of ovarian and endometrial cancers: Results from the Copenhagen School Health Records Register. Gynecologic Oncology, 2018, 148, 547-552.	0.6	4
119	Accelerating cervical cancer control and prevention. Lancet Public Health, The, 2018, 3, e6-e7.	4.7	13
120	Challenges in risk estimation using routinely collected clinical data: The example of estimating cervical cancer risks from electronic health-records. Preventive Medicine, 2018, 111, 429-435.	1.6	15
121	Reported Incidence and Survival of Fallopian Tube Carcinomas: A Population-Based Analysis From the North American Association of Central Cancer Registries. Journal of the National Cancer Institute, 2018, 110, 750-757.	3.0	28
122	Low Risk of Cervical Cancer/Precancer Among Most Women Under Surveillance Postcolposcopy. Journal of Lower Genital Tract Disease, 2018, 22, 97-103.	0.9	5
123	A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. Cancer Cell, 2018, 33, 690-705.e9.	7.7	478
124	A prospective study of risk-based colposcopy demonstrates improved detection of cervicalÂprecancers. American Journal of Obstetrics and Gynecology, 2018, 218, 604.e1-604.e8.	0.7	23
125	Alcohol and oestrogen metabolites in postmenopausal women in the Women's Health Initiative Observational Study. British Journal of Cancer, 2018, 118, 448-457.	2.9	14
126	Polycystic Ovary Syndrome, Oligomenorrhea, and Risk of Ovarian Cancer Histotypes: Evidence from the Ovarian Cancer Association Consortium. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 174-182.	1.1	20

#	Article	IF	CITATIONS
127	Epidemiologic Evidence That Excess Body Weight Increases Risk of Cervical Cancer by Decreased Detection of Precancer. Journal of Clinical Oncology, 2018, 36, 1184-1191.	0.8	65
128	Cytologic patterns of cervical adenocarcinomas with emphasis on factors associated with underdiagnosis. Cancer Cytopathology, 2018, 126, 950-958.	1.4	12
129	Population Testing for High Penetrance Genes: Are We There Yet?. Journal of the National Cancer Institute, 2018, 110, 687-689.	3.0	6
130	Strategies for screening and early detection of anal cancers: A narrative and systematic review and metaâ€analysis of cytology, HPV testing, and other biomarkers. Cancer Cytopathology, 2018, 126, 447-460.	1.4	72
131	Association of Endometrial Cancer Risk With Postmenopausal Bleeding in Women. JAMA Internal Medicine, 2018, 178, 1210.	2.6	233
132	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Research, 2018, 78, 5419-5430.	0.4	54
133	Effect of Several Negative Rounds of Human Papillomavirus and Cytology Co-testing on Safety Against Cervical Cancer. Annals of Internal Medicine, 2018, 168, 20.	2.0	50
134	Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. PLoS ONE, 2018, 13, e0197561.	1.1	9
135	HLAandKIRAssociations of Cervical Neoplasia. Journal of Infectious Diseases, 2018, 218, 2006-2015.	1.9	22
136	Identification of nine new susceptibility loci for endometrial cancer. Nature Communications, 2018, 9, 3166.	5.8	178
137	rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. International Journal of Molecular Sciences, 2018, 19, 2473.	1.8	3
138	In Defense of a Simplified, Practical Colposcopic Terminology. Journal of Lower Genital Tract Disease, 2018, 22, 233-234.	0.9	0
139	Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci. British Journal of Cancer, 2017, 116, 524-535.	2.9	23
140	Cigarette smoking is associated with adverse survival among women with ovarian cancer: Results from a pooled analysis of 19 studies. International Journal of Cancer, 2017, 140, 2422-2435.	2.3	25
141	Pre-diagnosis insulin-like growth factor-I and risk of epithelial invasive ovarian cancer by histological subtypes: A collaborative re-analysis from the Ovarian Cancer Cohort Consortium. Cancer Causes and Control, 2017, 28, 429-435.	0.8	3
142	Discovery and validation of candidate host DNA methylation markers for detection of cervical precancer and cancer. International Journal of Cancer, 2017, 141, 701-710.	2.3	62
143	Trends in cervical cancer incidence in younger US women from 2000 to 2013. Gynecologic Oncology, 2017, 144, 391-395.	0.6	10
144	Preparing for the Next Round of ASCCP-Sponsored Cervical Screening and Management Guidelines. Journal of Lower Genital Tract Disease, 2017, 21, 87-90.	0.9	23

#	Article	IF	CITATIONS
145	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	9.4	356
146	Androgens Are Differentially Associated with Ovarian Cancer Subtypes in the Ovarian Cancer Cohort Consortium. Cancer Research, 2017, 77, 3951-3960.	0.4	48
147	Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium. British Journal of Cancer, 2017, 116, 1223-1228.	2.9	13
148	HPV-based cervical cancer screening- facts, fiction, and misperceptions. Preventive Medicine, 2017, 98, 33-35.	1.6	43
149	Eurogin 2016 Roadmap: how HPV knowledge is changing screening practice. International Journal of Cancer, 2017, 140, 2192-2200.	2.3	83
150	Improvement in 5-Year Survival Rates for the Most Common Types of Cancer, 1975-2012. Journal of the National Cancer Institute, 2017, 109, .	3.0	18
151	From clinical epidemiology to practice recommendations: Knowledge gaps and uncertainty in the management of anal precancers. Cancer, 2017, 123, 4530-4534.	2.0	7
152	Evidence-Based Consensus Recommendations for Colposcopy Practice for Cervical Cancer Prevention in the United States. Journal of Lower Genital Tract Disease, 2017, 21, 216-222.	0.9	71
153	ASCCP Colposcopy Standards: Risk-Based Colposcopy Practice. Journal of Lower Genital Tract Disease, 2017, 21, 230-234.	0.9	56
154	Risks of CIN 2+, CIN 3+, and Cancer by Cytology and Human Papillomavirus Status: The Foundation of Risk-Based Cervical Screening Guidelines. Journal of Lower Genital Tract Disease, 2017, 21, 261-267.	0.9	55
155	Smoking and subsequent human papillomavirus infection: a mediation analysis. Annals of Epidemiology, 2017, 27, 724-730.e1.	0.9	33
156	Sitting, physical activity, and serum oestrogen metabolism in postmenopausal women: the Women's Health Initiative Observational Study. British Journal of Cancer, 2017, 117, 1070-1078.	2.9	14
157	HPV16 E7 Genetic Conservation Is Critical to Carcinogenesis. Cell, 2017, 170, 1164-1174.e6.	13.5	221
158	Anthropometric measures and serum estrogen metabolism in postmenopausal women: the Women's Health Initiative Observational Study. Breast Cancer Research, 2017, 19, 28.	2.2	21
159	Genotyping for Human Papillomavirus Types 16 and 18 in Women With Minor Cervical Lesions. Annals of Internal Medicine, 2017, 166, 118.	2.0	53
160	Prediagnostic circulating inflammation markers and endometrial cancer risk in the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial. International Journal of Cancer, 2017, 140, 600-610.	2.3	48
161	Proof-of-principle study of a novel cervical screening and triage strategy: Computer-analyzed cytology to decide which HPV-positive women are likely to have ≥CIN2. International Journal of Cancer, 2017, 140, 718-725.	2.3	19
162	Distribution of cell types differs in Papanicolaou tests of squamous cell carcinomas and adenocarcinomas. Journal of the American Society of Cytopathology, 2017, 6, 10-15.	0.2	3

#	Article	IF	CITATIONS
163	Somatic Host Cell Alterations in HPV Carcinogenesis. Viruses, 2017, 9, 206.	1.5	55
164	Associations between self-reported diabetes and 78 circulating markers of inflammation, immunity, and metabolism among adults in the United States. PLoS ONE, 2017, 12, e0182359.	1.1	7
165	Defining the genetic susceptibility to cervical neoplasia—A genome-wide association study. PLoS Genetics, 2017, 13, e1006866.	1.5	105
166	Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials. Oncotarget, 2017, 8, 84579-84594.	0.8	23
167	Three new pancreatic cancer susceptibility signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21. Oncotarget, 2016, 7, 66328-66343.	0.8	88
168	Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. International Journal of Epidemiology, 2016, 45, 884-895.	0.9	71
169	Reply to HPV test results provide useful risk stratification information in women with ASCâ€H Pap test findings. Cancer Cytopathology, 2016, 124, 754-755.	1.4	0
170	Exome genotyping arrays to identify rare and low frequency variants associated with epithelial ovarian cancer risk. Human Molecular Genetics, 2016, 25, 3600-3612.	1.4	17
171	Triage of <scp>ASCâ€H</scp> : A metaâ€analysis of the accuracy of highâ€risk <scp>HPV</scp> testing and other markers to detect cervical precancer. Cancer Cytopathology, 2016, 124, 261-272.	1.4	25
172	Similar Risk Patterns After Cervical Screening in Two Large U.S. Populations. Obstetrics and Gynecology, 2016, 128, 1248-1257.	1.2	22
173	Carcinogenic human papillomavirus infection. Nature Reviews Disease Primers, 2016, 2, 16086.	18.1	615
174	Insulin/IGF and sex hormone axes in human endometrium and associations with endometrial cancer risk factors. Cancer Causes and Control, 2016, 27, 737-748.	0.8	34
175	Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. Human Genetics, 2016, 135, 741-756.	1.8	19
176	Response. Journal of the National Cancer Institute, 2016, 108, djv390.	3.0	0
177	HPV16 Sublineage Associations With Histology-Specific Cancer Risk Using HPV Whole-Genome Sequences in 3200 Women. Journal of the National Cancer Institute, 2016, 108, djw100.	3.0	147
178	Serum Estrogens and Estrogen Metabolites and Endometrial Cancer Risk among Postmenopausal Women. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1081-1089.	1.1	76
179	Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. International Journal of Epidemiology, 2016, 45, 1619-1630.	0.9	111
180	The population impact of human papillomavirus/cytology cervical cotesting at 3â€year intervals: Reduced cervical cancer risk and decreased yield of precancer per screen. Cancer, 2016, 122, 3682-3686.	2.0	15

#	Article	IF	CITATIONS
181	Telomere structure and maintenance gene variants and risk of five cancer types. International Journal of Cancer, 2016, 139, 2655-2670.	2.3	43
182	A cohort study of cervical screening using partial HPV typing and cytology triage. International Journal of Cancer, 2016, 139, 2606-2615.	2.3	68
183	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. Cancer Discovery, 2016, 6, 1052-1067.	7.7	157
184	Genomic characterization of viral integration sites in HPVâ€related cancers. International Journal of Cancer, 2016, 139, 2001-2011.	2.3	113
185	Female chromosome X mosaicism is age-related and preferentially affects the inactivated X chromosome. Nature Communications, 2016, 7, 11843.	5.8	86
186	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast–ovarian cancer susceptibility locus. Nature Communications, 2016, 7, 12675.	5.8	78
187	Biomarkers for Cervical Cancer Prevention Programs: The Long and Winding Road From Discovery to Clinical Use. Journal of Lower Genital Tract Disease, 2016, 20, 191-194.	0.9	7
188	Ovarian Cancer Risk Factors by Histologic Subtype: An Analysis From the Ovarian Cancer Cohort Consortium. Journal of Clinical Oncology, 2016, 34, 2888-2898.	0.8	349
189	Circulating Estrogens and Postmenopausal Ovarian Cancer Risk in the Women's Health Initiative Observational Study. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 648-656.	1.1	47
190	Recreational physical inactivity and mortality in women with invasive epithelial ovarian cancer: evidence from the Ovarian Cancer Association Consortium. British Journal of Cancer, 2016, 115, 95-101.	2.9	39
191	Risk assessment to guide cervical screening strategies in a large <scp>C</scp> hinese population. International Journal of Cancer, 2016, 138, 2639-2647.	2.3	16
192	Natural Acquired Immunity Against Subsequent Genital Human Papillomavirus Infection: A Systematic Review and Meta-analysis. Journal of Infectious Diseases, 2016, 213, 1444-1454.	1.9	96
193	Triage of HPV positive women in cervical cancer screening. Journal of Clinical Virology, 2016, 76, S49-S55.	1.6	236
194	Assessment of Multifactor Gene–Environment Interactions and Ovarian Cancer Risk: Candidate Genes, Obesity, and Hormone-Related Risk Factors. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 780-790.	1.1	10
195	The association between socioeconomic status and tumour stage at diagnosis of ovarian cancer: A pooled analysis of 18 case-control studies. Cancer Epidemiology, 2016, 41, 71-79.	0.8	20
196	Chromosomal copy number alterations and HPV integration in cervical precancer and invasive cancer. Carcinogenesis, 2016, 37, 188-196.	1.3	41
197	Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. Oncotarget, 2016, 7, 69097-69110.	0.8	5
198	Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration. Oncotarget, 2016, 7, 72381-72394.	0.8	13

#	Article	IF	CITATIONS
199	A targeted genetic association study of epithelial ovarian cancer susceptibility. Oncotarget, 2016, 7, 7381-7389.	0.8	7
200	Prognostic Relevance of HPV Infection and p16 Overexpression in Squamous Cell Anal Cancer. International Journal of Radiation Oncology Biology Physics, 2015, 93, 819-827.	0.4	62
201	PTEN expression in benign human endometrial tissue and cancer in relation to endometrial cancer risk factors. Cancer Causes and Control, 2015, 26, 1729-1736.	0.8	31
202	Epithelialâ€Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. Genetic Epidemiology, 2015, 39, 689-697.	0.6	22
203	Use of Primary High-Risk Human Papillomavirus Testing for Cervical Cancer Screening. Journal of Lower Genital Tract Disease, 2015, 19, 91-96.	0.9	64
204	Detection of HPV DNA in paraffin-embedded cervical samples: a comparison of four genotyping methods. BMC Infectious Diseases, 2015, 15, 544.	1.3	40
205	Issues in optimising and standardising the accuracy and utility of the colposcopic examination in the HPV era. Ecancermedicalscience, 2015, 9, 530.	0.6	17
206	Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk. PLoS ONE, 2015, 10, e0128106.	1.1	44
207	Body Mass Index Genetic Risk Score and Endometrial Cancer Risk. PLoS ONE, 2015, 10, e0143256.	1.1	13
208	Associations of Coffee Drinking with Systemic Immune and Inflammatory Markers. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1052-1060.	1.1	59
209	Characterization of Large Structural Genetic Mosaicism in Human Autosomes. American Journal of Human Genetics, 2015, 96, 487-497.	2.6	101
210	HPV16 CpG methyl-haplotypes are associated with cervix precancer and cancer in the Guanacaste natural history study. Gynecologic Oncology, 2015, 138, 94-100.	0.6	10
211	Risk factors for endometrial cancer in black and white women: a pooled analysis from the epidemiology of endometrial cancer consortium (E2C2). Cancer Causes and Control, 2015, 26, 287-296.	0.8	40
212	Use of primary high-risk human papillomavirus testing for cervical cancer screening: Interim clinical guidance. Gynecologic Oncology, 2015, 136, 178-182.	0.6	374
213	Metabolic Syndrome and Risk of Endometrial Cancer in the United States: A Study in the SEER–Medicare Linked Database. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 261-267.	1.1	109
214	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 2015, 47, 164-171.	9.4	221
215	Cell-Cycle Protein Expression in a Population-Based Study of Ovarian and Endometrial Cancers. Frontiers in Oncology, 2015, 5, 25.	1.3	19
216	The Pill's gestation: from birth control to cancer prevention. Lancet Oncology, The, 2015, 16, 1004-1006.	5.1	7

#	Article	IF	CITATIONS
217	Deep sequencing of HPV16 genomes: A new high-throughput tool for exploring the carcinogenicity and natural history of HPV16 infection. Papillomavirus Research (Amsterdam, Netherlands), 2015, 1, 3-11.	4.5	75
218	Network-Based Integration of GWAS and Gene Expression Identifies a <i>HOX</i> -Centric Network Associated with Serous Ovarian Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1574-1584.	1.1	28
219	Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium. Clinical Cancer Research, 2015, 21, 5264-5276.	3.2	33
220	A study of HPV typing for the management of HPV-positive ASC-US cervical cytologic results. Gynecologic Oncology, 2015, 138, 573-578.	0.6	49
221	The Role of Human Papillomavirus Genotyping in Cervical Cancer Screening: A Large-Scale Evaluation of the cobas HPV Test. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1304-1310.	1.1	44
222	Detection of endometrial cancer via molecular analysis of DNA collected with vaginal tampons. Gynecologic Oncology, 2015, 137, 14-22.	0.6	79
223	Evaluating the ovarian cancer gonadotropin hypothesis: A candidate gene study. Gynecologic Oncology, 2015, 136, 542-548.	0.6	15
224	Hormone therapy: short-term relief, long-term consequences. Lancet, The, 2015, 385, 1806-1808.	6.3	22
225	Attributing Oncogenic Human Papillomavirus Genotypes to High-grade Cervical Neoplasia. American Journal of Surgical Pathology, 2015, 39, 496-504.	2.1	31
226	Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. Nature Communications, 2015, 6, 8234.	5.8	63
227	Common variants at the <i>CHEK2</i> gene locus and risk of epithelial ovarian cancer. Carcinogenesis, 2015, 36, 1341-1353.	1.3	24
228	Towards therapeutic vaccination against cervical precancer?. Lancet, The, 2015, 386, 2036-2038.	6.3	1
229	Molecular transitions from papillomavirus infection to cervical precancer and cancer: Role of stromal estrogen receptor signaling. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E3255-64.	3.3	197
230	p16/Ki-67 Dual Stain Cytology for Detection of Cervical Precancer in HPV-Positive Women. Journal of the National Cancer Institute, 2015, 107, djv257.	3.0	130
231	Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. Human Molecular Genetics, 2015, 24, 5955-5964.	1.4	68
232	Multiple Biopsies and Detection of Cervical Cancer Precursors at Colposcopy. Journal of Clinical Oncology, 2015, 33, 83-89.	0.8	156
233	Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC). Journal of Genetics and Genome Research, 2015, 2, .	0.3	25
234	Exome-Wide Association Study of Endometrial Cancer in a Multiethnic Population. PLoS ONE, 2014, 9, e97045.	1.1	12

#	Article	IF	CITATIONS
235	Variation in NF-κB Signaling Pathways and Survival in Invasive Epithelial Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1421-1427.	1.1	13
236	Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. Human Molecular Genetics, 2014, 23, 6616-6633.	1.4	90
237	p16INK4a Immunohistochemistry in Cervical Biopsy Specimens. American Journal of Clinical Pathology, 2014, 142, 767-772.	0.4	51
238	Cigarette Smoking and Variations in Systemic Immune and Inflammation Markers. Journal of the National Cancer Institute, 2014, 106, .	3.0	255
239	Reassurance Against Future Risk of Precancer and Cancer Conferred by a Negative Human Papillomavirus Test. Journal of the National Cancer Institute, 2014, 106, dju153-dju153.	3.0	200
240	Response. Journal of the National Cancer Institute, 2014, 107, dju390-dju390.	3.0	0
241	Seroprevalence of 8 Oncogenic Human Papillomavirus Genotypes and Acquired Immunity Against Reinfection. Journal of Infectious Diseases, 2014, 210, 448-455.	1.9	33
242	Analytic and Clinical Performance of cobas HPV Testing in Anal Specimens from HIV-Positive Men Who Have Sex with Men. Journal of Clinical Microbiology, 2014, 52, 2892-2897.	1.8	29
243	Discovery and validation of methylation markers for endometrial cancer. International Journal of Cancer, 2014, 135, 1860-1868.	2.3	62
244	No Evidence for Synergy Between Human Papillomavirus Genotypes for the Risk of High-Grade Squamous Intraepithelial Lesions in a Large Population-Based Study. Journal of Infectious Diseases, 2014, 209, 855-864.	1.9	46
245	Kernel canonical correlation analysis for assessing gene–gene interactions and application to ovarian cancer. European Journal of Human Genetics, 2014, 22, 126-131.	1.4	33
246	Talc Use and Ovarian Cancer: Epidemiology Between a Rock and a Hard Place. Journal of the National Cancer Institute, 2014, 106, dju260-dju260.	3.0	14
247	Pre-diagnostic serum levels of inflammation markers and risk of ovarian cancer in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial. Gynecologic Oncology, 2014, 135, 297-304.	0.6	83
248	Aspirin, Nonaspirin Nonsteroidal Anti-inflammatory Drug, and Acetaminophen Use and Risk of Invasive Epithelial Ovarian Cancer: A Pooled Analysis in the Ovarian Cancer Association Consortium. Journal of the National Cancer Institute, 2014, 106, djt431-djt431.	3.0	186
249	Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer. Nature Genetics, 2014, 46, 994-1000.	9.4	294
250	Body Mass Index, Physical Activity, and Serum Markers of Inflammation, Immunity, and Insulin Resistance. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 2840-2849.	1.1	79
251	Filling a gap in cervical cancer screening programmes. Lancet Oncology, The, 2014, 15, 249-251.	5.1	18
252	Factors associated with reduced accuracy in Papanicolaou tests for patients with invasive cervical cancer. Cancer Cytopathology, 2014, 122, 694-701.	1.4	14

#	Article	IF	CITATIONS
253	Evaluation of clinical performance of a novel urine-based HPV detection assay among women attending a colposcopy clinic. Journal of Clinical Virology, 2014, 60, 414-417.	1.6	18
254	Interobserver reproducibility and accuracy of p16/ <scp>K</scp> iâ€67 dualâ€stain cytology in cervical cancer screening. Cancer Cytopathology, 2014, 122, 914-920.	1.4	51
255	Heterogeneity of highâ€grade cervical intraepithelial neoplasia related to HPV16: Implications for natural history and management. International Journal of Cancer, 2013, 132, 148-154.	2.3	28
256	Human Papillomavirus Infection and the Multistage Carcinogenesis of Cervical Cancer. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 553-560.	1.1	223
257	Type I and II Endometrial Cancers: Have They Different Risk Factors?. Journal of Clinical Oncology, 2013, 31, 2607-2618.	0.8	613
258	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 2013, 45, 371-384.	9.4	493
259	From Differences in Means between Cases and Controls to Risk Stratification: A Business Plan for Biomarker Development. Cancer Discovery, 2013, 3, 148-157.	7.7	65
260	Triage of HPV-positive women in cervical cancer screening. Lancet Oncology, The, 2013, 14, 107-109.	5.1	32
261	Endometrial Cancer Risk Factors by 2 Main Histologic Subtypes. American Journal of Epidemiology, 2013, 177, 142-151.	1.6	84
262	A Comparison of Human Papillomavirus Genotype-Specific DNA and E6/E7 mRNA Detection to Identify Anal Precancer among HIV-Infected Men Who Have Sex with Men. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 42-49.	1.1	23
263	2012 Updated Consensus Guidelines for the Management of Abnormal Cervical Cancer Screening Tests and Cancer Precursors. Obstetrics and Gynecology, 2013, 121, 829-846.	1.2	617
264	Methylation of HPV18, HPV31, and HPV45 Genomes and Cervical Intraepithelial Neoplasia Grade 3. Journal of the National Cancer Institute, 2012, 104, 1738-1749.	3.0	119
265	Age at Last Birth in Relation to Risk of Endometrial Cancer: Pooled Analysis in the Epidemiology of Endometrial Cancer Consortium. American Journal of Epidemiology, 2012, 176, 269-278.	1.6	76
266	Human Papillomavirus Load Measured by Linear Array Correlates with Quantitative PCR in Cervical Cytology Specimens. Journal of Clinical Microbiology, 2012, 50, 1564-1570.	1.8	26
267	Human papillomavirus genotyping, human papillomavirus mRNA expression, and p16/Ki-67 cytology to detect anal cancer precursors in HIV-infected MSM. Aids, 2012, 26, 2185-2192.	1.0	70
268	Screening for anal cancer: endpoints needed. Lancet Oncology, The, 2012, 13, 438-440.	5.1	20
269	Performance of p16/Ki-67 Immunostaining to Detect Cervical Cancer Precursors in a Colposcopy Referral Population. Clinical Cancer Research, 2012, 18, 4154-4162.	3.2	196
270	Human Papillomavirus DNA Methylation as a Potential Biomarker for Cervical Cancer. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 2125-2137.	1.1	143

#	Article	IF	CITATIONS
271	Effectiveness of a simple rapid human papillomavirus DNA test in rural Nigeria. International Journal of Cancer, 2012, 131, 2903-2909.	2.3	51
272	p16 <sup>INK4a</sup> immunocytochemistry versus human papillomavirus testing for triage of women with minor cytologic abnormalities. Cancer Cytopathology, 2012, 120, 294-307.	1.4	70
273	Human Papillomavirus Testing in the Prevention of Cervical Cancer. Journal of the National Cancer Institute, 2011, 103, 368-383.	3.0	583
274	Genetic Variation on 9p22 Is Associated with Abnormal Ovarian Ultrasound Results in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. PLoS ONE, 2011, 6, e21731.	1.1	10
275	Hierarchical Clustering of Human Papilloma Virus Genotype Patterns in the ASCUS-LSIL Triage Study. Cancer Research, 2010, 70, 8578-8586.	0.4	25
276	Human Papillomavirus Cofactors by Disease Progression and Human Papillomavirus Types in the Study to Understand Cervical Cancer Early Endpoints and Determinants. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 113-120.	1.1	76
277	A Study of Amplicor Human Papillomavirus DNA Detection in the Atypical Squamous Cells of Undetermined Significance–Low-Grade Squamous Intraepithelial Lesion Triage Study. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 1341-1349.	1.1	20
278	Cervical Cancer Control in the Era of HPV Vaccination and Novel Biomarkers. Pathobiology, 2009, 76, 82-89.	1.9	15
279	Utility of methylation markers in cervical cancer early detection: Appraisal of the state-of-the-science. Gynecologic Oncology, 2009, 112, 293-299.	0.6	247
280	Accuracy of cervical specimens obtained for biomarker studies in women with CIN3. Gynecologic Oncology, 2009, 115, 493-496.	0.6	24
281	Grading the severity of cervical neoplasia based on combined histopathology, cytopathology, and HPV genotype distribution among 1,700 women referred to colposcopy in Oklahoma. International Journal of Cancer, 2009, 124, 964-969.	2.3	76
282	Multiple human papillomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinants. International Journal of Cancer, 2009, 125, 2151-2158.	2.3	165
283	How to evaluate emerging technologies in cervical cancer screening?. International Journal of Cancer, 2009, 125, 2489-2496.	2.3	91
284	Human Papillomavirus mRNA and p16 Detection as Biomarkers for the Improved Diagnosis of Cervical Neoplasia. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 2536-2545.	1.1	224
285	No Metastatic Cervical Adenocarcinomas in a Series of p16INK4a-Positive Mucinous or Endometrioid Advanced Ovarian Carcinomas. International Journal of Gynecological Pathology, 2008, 27, 18-23.	0.9	21
286	Biomarkers in Cervical Cancer Screening. Disease Markers, 2007, 23, 315-330.	0.6	175
287	Expression of an endogenous retroviral sequence from the HERV-H group in gastrointestinal cancers. International Journal of Cancer, 2007, 121, 1417-1423.	2.3	49
288	Identification of high-grade cervical dysplasia by the detection of p16INK4a in cell lysates obtained from cervical samples. Cancer, 2006, 107, 2307-2313.	2.0	38

#	Article	IF	CITATIONS
289	Triage of women with ASCUS and LSIL cytology. Cancer, 2006, 111, 58-66.	2.0	74
290	Evaluation of a nuclear score for p16INK4a-stained cervical squamous cells in liquid-based cytology samples. Cancer, 2005, 105, 461-467.	2.0	95
291	Identification of differentially expressed genes in colorectal adenoma compared to normal tissue by suppression subtractive hybridization. International Journal of Oncology, 2004, 24, 987-94.	1.4	15
292	Characterization of viral-cellular fusion transcripts in a large series of HPV16 and 18 positive anogenital lesions. Oncogene, 2002, 21, 419-426.	2.6	126